

Table S5: Clinical and procedural characteristics of female and male patients without concomitant atrial fibrillation before and after propensity score matching. Data presented as percentages or mean \pm SD. * - Data presented as median with interquartile range (IQR). # - MR grade according to American Society of Echocardiography (ASE) classification. AF – atrial fibrillation. COPD – chronic obstructive pulmonary disease. CABG – coronary artery bypass graft surgery. PCI – percutaneous coronary intervention. ICD – implantable cardioverter defibrillator. CRT – cardiac resynchronization therapy. GFR – glomerular filtration rate. LV function – left ventricular function. LA – left atrial. NT-proBNP – N-terminal pro-B-type natriuretic peptide. TR – tricuspid regurgitation. MR – mitral regurgitation. MACCE – major adverse cardiac and cerebrovascular events. AAD – antiarrhythmic drugs. ACE – angiotensin converting enzyme. AT1 – angiotensin II type 1 receptor. ARN – angiotensin receptor neprylisin. SGLT-II – sodium-glucose transporter 2.

| Variable | Before Propensity-Score-Matching | | | | After Propensity-Score-Matching | | |
|------------------|----------------------------------|------------------|-----------------|------------------|---------------------------------|----------------|-----------------|
| | Overall (n=213) | Female (n=90) | Male (n=123) | <i>p</i> -value | Female (n=90) | Male (n=90) | <i>p</i> -value |
| Age (years) | 77 \pm 9 | 79 \pm 8 | 75 \pm 9 | <0.001 | 79 \pm 8 | 77 \pm 8 | 0.06 |
| euroSCORE II* | 16 (18.1) | 15 (17.1) | 16.7 (18.5) | 0.5 | 15 (17.1) | 16 (19.6) | 0.5 |
| STS Risk Score* | 5.9 (7.6) | 5.5 (5.5) | 6.9 (8.8) | 0.06 | 5.5 (5.5) | 6 (7.4) | 0.4 |
| NYHA class I | 0% (0) | 0% (0) | 0% (0) | 0.3 | 0% (0) | 0% (0) | 0.4 |
| NYHA class II | 4.2% (9) | 6.7% (6) | 2.4% (3) | | 6.7% (6) | 2.2% (6) | |
| NYHA class III | 77.5% (165) | 75.6% (68) | 78.9% (97) | | 75.6% (68) | 80% (68) | |
| NYHA class IV | 18% (39) | 17.8% (16) | 18.7% (23) | | 17.8% (16) | 17.8% (16) | |
| COPD | 20.2% (43) | 18.9% (17) | 21.1% (26) | 0.7 | 18.9% (17) | 18.9% (17) | 1 |
| CAD | 67.1% (143) | 58.9% (53) | 73.2% (90) | 0.04 | 58.9% (53) | 66.7% (60) | 0.4 |
| Prior CAB-OP | 33.8% (72) | 22.2% (20) | 42.3% (52) | 0.003 | 22.2% (20) | 32.2% (29) | 0.2 |
| Prior PCI | 57.7% (123) | 56.7% (51) | 58.5% (72) | 0.9 | 56.7% (51) | 54.4% (49) | 0.9 |
| Pre-existing ICD | 20.2% (43) | 7.8% (7) | 29.3% (36) | <0.001 | 7.8% (7) | 11.1% (10) | 0.6 |

| | | | | | | | |
|--|-------------|-------------|-------------|------------------|-------------|-------------|------|
| Pre-existing CRT | 12.2% (26) | 3.3% (3) | 18.7% (23) | <0.001 | 3.3% (3) | 12.2% (11) | 0.06 |
| Diabetes mellitus | 31% (66) | 30% (27) | 31.7% (39) | 0.9 | 30% (27) | 31.1% (28) | 1 |
| Arterial hypertension | 76.1% (162) | 68.9% (62) | 81.3% (100) | 0.05 | 68.9% (62) | 81.1% (73) | 0.08 |
| Prior Stroke | 7.4% (16) | 8.9% (8) | 6.5% (8) | 0.6 | 8.9% (8) | 6.7% (6) | 0.8 |
| LVEF ≥50% | 33.8% (72) | 45.6% (41) | 25.2% (31) | 0.004 | 45.6% (41) | 32.2% (29) | 0.2 |
| LVEF 41-49% | 9.4% (20) | 10% (9) | 8.9% (11) | | 10% (9) | 11.1% (10) | |
| LVEF ≤40% | 56.8% (121) | 44.4% (40) | 65.9% (81) | | 44.4% (40) | 56.7% (51) | |
| GFR (mL/Min) | 54 ± 25 | 54.9 ± 23 | 53.5 ± 26 | 0.7 | 54.9 ± 23 | 54 ± 26 | 0.8 |
| NT-proBNP (ng/L)* | 2069 (5727) | 2080 (4437) | 2069 (6005) | 0.4 | 2080 (4437) | 2068 (6807) | 0.4 |
| TR grade III | 10.8% (23) | 10% (9) | 11.4% (14) | 0.8 | 10% (9) | 8.9% (8) | 1 |
| Degenerative MR etiology | 35.7% (76) | 35.6% (32) | 35.8% (44) | 0.3 | 35.6% (32) | 38.9% (35) | 0.5 |
| Functional MR etiology | 55.4% (118) | 52.2% (47) | 57.7% (71) | | 52.2% (47) | 54.4% (49) | |
| Mixed MR etiology | 8.9% (19) | 12.2% (11) | 6.5% (8) | | 12.2% (11) | 6.7% (6) | |
| Median procedure duration (min)* | 80 (60) | 77.5 (46.5) | 85 (61.5) | 0.1 | 77.5 (46.5) | 82 (63) | 0.2 |
| Number of clips implanted* | 1 (1) | 1 (1) | 1 (2) | 0.052 | 1 (1) | 1.5 (1) | 0.2 |
| Periprocedural MR reduction [#] | Δ2.0 ± 0.6 | Δ1.9 ± 0.6 | Δ2.0 ± 0.6 | 0.3 | Δ1.9 ± 0.6 | Δ2.0 ± 0.6 | 0.4 |
| Length of hospital stay (days)* | 6 (4) | 6.5 (4) | 6 (5) | 0.6 | 6.5 (4) | 6 (5) | 0.5 |
| Overall-MACCE | 6.6% (14) | 6.7% (6) | 6.5% (8) | 1 | 6.7% (6) | 8.9% (8) | 0.8 |
| Cerebral/systemic thromboembolic event | 0.5% (1) | 0% (0) | 0.8% (1) | 1 | 0% (0) | 1.1% (1) | 1 |

| | | | | | | | |
|---|-------------|------------|-------------|-------------|------------|------------|-----|
| <i>Bleeding requiring intervention</i> | 1.9% (4) | 4.4% (4) | 3.3% (4) | 0.7 | 4.4% (4) | 4.4% (4) | 1 |
| <i>In-hospital death from cardiovasc. cause</i> | 2.3% (5) | 2.2% (2) | 2.4% (3) | 1 | 2.2% (2) | 3.3% (3) | 1 |
| In-hospital death from any cause | 4.2% (9) | 3.3% (3) | 4.9% (6) | 0.7 | 3.3% (3) | 4.4% (4) | 1 |
| Heart Failure Therapy | | | | | | | |
| ACE-/AT1 Inhibitors | 72.3% (154) | 80% (72) | 66.7% (82) | 0.04 | 80% (72) | 68.9% (62) | 0.1 |
| ARN Inhibitor | 13.1% (28) | 7.8% (7) | 17.1% (21) | 0.06 | 7.8% (7) | 12.2% (11) | 0.5 |
| Beta Blockers | 87.8% (187) | 87.8% (79) | 87.8% (108) | 1 | 87.8% (79) | 86.7% (78) | 1 |
| Loop diuretics | 87.8% (187) | 90% (81) | 86.2% (106) | 0.5 | 90% (81) | 86.7% (78) | 0.6 |
| Thiazid diuretics | 16.4% (35) | 13.3% (12) | 18.7% (23) | 0.4 | 13.3% (12) | 18.9% (17) | 0.4 |
| Aldosteron antagonists | 46.5% (99) | 41.1% (37) | 50.4% (62) | 0.2 | 41.1% (37) | 50% (45) | 0.3 |
| Ivabradin | 2.8% (6) | 1.1% (1) | 4.1% (5) | 0.4 | 1.1% (1) | 3.3% (3) | 0.6 |
| Digitalis | 0.5% (1) | 0% (0) | 0.8% (1) | 1 | 0% (0) | 1.1% (1) | 1 |
| SGLT-II-Inhibitors | 6.1% (13) | 3.3% (3) | 8.1% (10) | 0.2 | 3.3% (3) | 7.8% (7) | 0.3 |
| Vericiguat | 0% (0) | 0% (0) | 0% (0) | 1 | 0% (0) | 0% (0) | 1 |